Baseline characteristics
| Characteristics | HA+CS (N=181) | Standard care (N=95) | p Value |
|---|---|---|---|
| Age—mean (SD) | 55.24 (17.33) | 48.84 (21.16) | 0.017 |
| Employed—n (%) | 83 (46) | 62 (65) | 0.003 |
| Partner—n (%) | 148 (82) | 72 (76) | 0.172 |
| Sexually active—n (%) | 114 (63) | 60 (63) | 0.931 |
| Menopause—n (%) | 69 (28) | 49 (51) | 0.038 |
| BMI—mean (SD) | 26.20 (6.37) | 24.56 (5.03) | 0.019 |
| Postcoital infections—n (%) | 31 (17) | 29 (31) | 0.012 |
| Dyspareunia—n (%) | 40 (22) | 5 (5) | <0.001 |
| Severity RUTI—median (IQR)* | 4 (2–5) | 4 (3–4) | 0.316 |
| Prophylaxis—n (%) | |||
| Antimicrobial prophylaxis continuous | NA | 42 (44.21) | |
| Antimicrobial prophylaxis postcoital | NA | 19 (20) | |
| Intermittent immunoactive prophylaxis | NA | 28 (29.47) | |
| On demand immunoactive therapy | NA | 1 (1.05) | |
| Others | NA | 5 (5.26) | |
| FSFI—mean (SD) | 5.35 (8.71) | 3.13 (5.43) | 0.018 |
| EQ-5D—median (IQR) | 0.69 (0.24–0.73)† | 0.69 (0.28–0.81)‡ | 0.696 |
| SF-36 PCS—median (IQR) | 60 (54.5–70)§ | 60 (53–67.5)¶ | 0.500 |
| SF-36 MCS—median (IQR) | 60 (54–70)** | 60 (53–67.5)¶ | 0.551 |
*According to the European Association of Urology Guidelines on Urological Infections where 1 is low severity cystitis and 6 is extreme severity including organ failure.21
†N=90 patients.
‡N=29 patients.
§N=72 patients.
¶N=60 patients.
**N=73 patients.
BMI, body mass index; EQ-5D, Euro QoL 5D 3 level; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; NA, not applicable; RUTI, recurrent urinary tract infection; SF-36 MCS, Short Form 36 mental component score; SF-36 PCS, Short Form 36 physical component score.